Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers.

Tursi A, Allegretta L, Buccianti N, Della Valle N, Elisei W, Forti G, Faggiani R, Gallina S, Hadad Y, Larussa T, Lauria A, Luzza F, Lorenzetti R, Mocci G, Penna A, Polimeni N, Pranzo G, Ricciardelli C, Zampaletta C, Picchio M.

J Gastrointestin Liver Dis. 2017 Sep;26(3):239-244. doi: 10.15403/jgld.2014.1121.263.trs.

2.

Cystic echinococcosis in cattle dairy farms: spatial distribution and epidemiological dynamics.

Scala A, Bosco A, Pipia AP, Tamponi C, Musella V, Costanzo N, Testoni F, Montisci A, Mocci G, Longhi A, Tilocca L, Rinaldi L, Cringoli G, Varcasia A.

Geospat Health. 2017 May 29;12(1):562. doi: 10.4081/gh.2017.562.

3.

SICUS and CEUS imaging in Crohn's disease: an update.

Mocci G, Migaleddu V, Cabras F, Sirigu D, Scanu D, Virgilio G, Marzo M.

J Ultrasound. 2017 Jan 2;20(1):1-9. doi: 10.1007/s40477-016-0230-5. eCollection 2017 Mar. Review.

4.

Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.

Tursi A, Allegretta L, Chiri S, Della Valle N, Elisei W, Forti G, Lorenzetti R, Mocci G, Penna A, Pranzo G, Ricciardelli C, Picchio M.

Minerva Gastroenterol Dietol. 2017 Dec;63(4):313-318. doi: 10.23736/S1121-421X.17.02402-3. Epub 2017 Mar 14.

PMID:
28293938
5.

Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study".

Fries W, Viola A, Manetti N, Frankovic I, Pugliese D, Monterubbianesi R, Scalisi G, Aratari A, Cantoro L, Cappello M, Samperi L, Saibeni S, Casella G, Mocci G, Rea M, Furfaro F, Contaldo A, Magarotto A, Calella F, Manguso F, Inserra G, Privitera AC, Principi M, Castiglione F, Caprioli F, Ardizzone S, Danese S, Papi C, Bossa F, Kohn A, Armuzzi A, D'Incà R, Annese V, Alibrandi A, Bonovas S, Fiorino G; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD).

Dig Liver Dis. 2017 Jan;49(1):17-23. doi: 10.1016/j.dld.2016.09.006. Epub 2016 Sep 21.

PMID:
27717794
6.

Management of perianal fistulas in Crohn's disease: an up-to-date review.

Marzo M, Felice C, Pugliese D, Andrisani G, Mocci G, Armuzzi A, Guidi L.

World J Gastroenterol. 2015 Feb 7;21(5):1394-403. doi: 10.3748/wjg.v21.i5.1394. Review.

7.

Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.

Guidi L, Marzo M, Andrisani G, Felice C, Pugliese D, Mocci G, Nardone O, De Vitis I, Papa A, Rapaccini G, Forni F, Armuzzi A.

Dig Liver Dis. 2014 Nov;46(11):974-9. doi: 10.1016/j.dld.2014.07.013. Epub 2014 Aug 2.

PMID:
25096964
8.

Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action.

Mocci G, Jiménez-Sánchez L, Adell A, Cortés R, Artigas F.

Neuropharmacology. 2014 Apr;79:49-58. doi: 10.1016/j.neuropharm.2013.10.021. Epub 2013 Nov 7.

PMID:
24211653
9.

FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents.

Guidi L, Felice C, Procoli A, Bonanno G, Martinelli E, Marzo M, Mocci G, Pugliese D, Andrisani G, Danese S, De Vitis I, Papa A, Armuzzi A, Rutella S.

Biomed Res Int. 2013;2013:286368. doi: 10.1155/2013/286368. Epub 2013 Aug 26.

10.

Repressive epigenetic changes at the mGlu2 promoter in frontal cortex of 5-HT2A knockout mice.

Kurita M, Moreno JL, Holloway T, Kozlenkov A, Mocci G, García-Bea A, Hanks JB, Neve R, Nestler EJ, Russo SJ, González-Maeso J.

Mol Pharmacol. 2013 Jun;83(6):1166-75. doi: 10.1124/mol.112.084582. Epub 2013 Mar 18.

11.

Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.

Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L.

J Crohns Colitis. 2013 Nov;7(10):769-79. doi: 10.1016/j.crohns.2013.01.009. Epub 2013 Mar 1. Review.

12.

Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function.

Moreno JL, Muguruza C, Umali A, Mortillo S, Holloway T, Pilar-Cuéllar F, Mocci G, Seto J, Callado LF, Neve RL, Milligan G, Sealfon SC, López-Giménez JF, Meana JJ, Benson DL, González-Maeso J.

J Biol Chem. 2012 Dec 28;287(53):44301-19. doi: 10.1074/jbc.M112.413161. Epub 2012 Nov 5.

13.

HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity.

Kurita M, Holloway T, García-Bea A, Kozlenkov A, Friedman AK, Moreno JL, Heshmati M, Golden SA, Kennedy PJ, Takahashi N, Dietz DM, Mocci G, Gabilondo AM, Hanks J, Umali A, Callado LF, Gallitano AL, Neve RL, Shen L, Buxbaum JD, Han MH, Nestler EJ, Meana JJ, Russo SJ, González-Maeso J.

Nat Neurosci. 2012 Sep;15(9):1245-54. doi: 10.1038/nn.3181. Epub 2012 Aug 5.

14.

Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants.

Andrisani G, Frasca D, Romero M, Armuzzi A, Felice C, Marzo M, Pugliese D, Papa A, Mocci G, De Vitis I, Rapaccini GL, Blomberg BB, Guidi L.

J Crohns Colitis. 2013 May;7(4):301-7. doi: 10.1016/j.crohns.2012.05.011. Epub 2012 Jun 5.

15.

Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.

Papa A, Felice C, Marzo M, Andrisani G, Armuzzi A, Covino M, Mocci G, Pugliese D, De Vitis I, Gasbarrini A, Rapaccini GL, Guidi L.

J Crohns Colitis. 2013 Mar;7(2):113-9. doi: 10.1016/j.crohns.2012.03.001. Epub 2012 Mar 30.

PMID:
22464811
16.

New biological agents for the treatment of the "high risk" IBD patients.

Guidi L, Marzo M, Felice C, Mocci G, Sparano L, Pugliese D, De Vitis I, Papa A, Armuzzi A.

Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):342-6. Review.

PMID:
20496545
17.

Biological therapies for inflammatory bowel disease: controversies and future options.

Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, Papa G, Gasbarrini A.

Expert Rev Clin Pharmacol. 2009 Jul;2(4):391-403. doi: 10.1586/ecp.09.12.

PMID:
22112183
18.

New therapeutic approach in inflammatory bowel disease.

Papa A, Mocci G, Scaldaferri F, Bonizzi M, Felice C, Andrisani G, Gasbarrini A.

Eur Rev Med Pharmacol Sci. 2009 Mar;13 Suppl 1:33-5. Review.

PMID:
19530509
19.

Use of infliximab in particular clinical settings: management based on current evidence.

Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, De Vitis I, Guidi L, Gasbarrini A.

Am J Gastroenterol. 2009 Jun;104(6):1575-86. doi: 10.1038/ajg.2009.162. Epub 2009 Apr 28. Review.

PMID:
19491875
20.

Treatment of Crohn's disease with colony-stimulating factors: An overview.

Guidi L, Mocci G, Marzo M, Rutella S.

Ther Clin Risk Manag. 2008 Oct;4(5):927-34.

21.

Sero-epidemiological update on sheep toxoplasmosis in Sardinia, Italy.

Natale A, Porqueddu M, Capelli G, Mocci G, Marras A, Sanna Coccone GN, Garippa G, Scala A.

Parassitologia. 2007 Dec;49(4):235-8.

PMID:
18689234
22.

Mediterranean shrubs as potential antioxidant sources.

Sanjust E, Mocci G, Zucca P, Rescigno A.

Nat Prod Res. 2008 May 20;22(8):689-708. doi: 10.1080/14786410801997125.

PMID:
18569710
23.

Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects.

Papa A, Scaldaferri F, Danese S, Guglielmo S, Roberto I, Bonizzi M, Mocci G, Felice C, Ricci C, Andrisani G, Fedeli G, Gasbarrini G, Gasbarrini A.

Dig Dis. 2008;26(2):149-55. doi: 10.1159/000116773. Epub 2008 Apr 21. Review.

PMID:
18431065
24.

Intima-media thickness in inflammatory bowel disease patients: a still open question.

Papa A, Bonizzi M, Andrisani G, Felice C, Mocci G, Gasbarrini A.

Am J Gastroenterol. 2008 Feb;103(2):490; author reply 490-1. doi: 10.1111/j.1572-0241.2007.01646_9.x. No abstract available.

PMID:
18289216

Supplemental Content

Support Center